David O Calligaro
Overview
Explore the profile of David O Calligaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
May P, Willis B, Lowe S, Dean R, Monk S, Cocke P, et al.
J Neurosci
. 2015 Jan;
35(3):1199-210.
PMID: 25609634
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of...
2.
Upadhyaya H, Desaiah D, Schuh K, Bymaster F, Kallman M, Clarke D, et al.
Psychopharmacology (Berl)
. 2013 Feb;
226(2):189-200.
PMID: 23397050
Rationale: Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because...
3.
Wright R, Johnson B, Zhang C, Salhoff C, Kingston A, Calligaro D, et al.
Neuropharmacology
. 2012 Feb;
66:89-98.
PMID: 22313530
Group II metabotropic glutamate (mGlu) receptor agonists were efficacious in randomized clinical research trials for schizophrenia and generalized anxiety disorder. The regional quantification of mGlu(2) and mGlu(3) receptors remains unknown....
4.
May P, Dean R, Lowe S, Martenyi F, Sheehan S, Boggs L, et al.
J Neurosci
. 2011 Nov;
31(46):16507-16.
PMID: 22090477
According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is critical for Alzheimer's disease (AD) pathogenesis. Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor...
5.
Nelson D, Phebus L, Johnson K, Wainscott D, Cohen M, Calligaro D, et al.
Cephalalgia
. 2010 Sep;
30(10):1159-69.
PMID: 20855361
Introduction: Lasmiditan (also known as COL-144 and LY573144; 2,4,6-trifluoro-N-[6-[(1-methylpiperidin-4-yl)carbonyl]pyridin-2yl]benzamide) is a high-affinity, highly selective serotonin (5-HT) 5-HT(1F) receptor agonist. Results: In vitro binding studies show a K(i) value of 2.21...
6.
Krushinski Jr J, Schaus J, Thompson D, Calligaro D, Nelson D, Luecke S, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(20):5600-4.
PMID: 17804228
Analogues of pindolol, 1-(1H-indol-4-yloxy)-3-isopropylamino-propan-2-ol, were synthesized and evaluated as 5-HT(1A) receptor antagonists. The structural features required for optimal binding to the 5-HT1A receptor are as follows: S-2-propanol linker, 4-indoloxy substituent,...
7.
Rorick-Kehn L, Johnson B, Burkey J, Wright R, Calligaro D, Marek G, et al.
J Pharmacol Exp Ther
. 2007 Jan;
321(1):308-17.
PMID: 17204749
Group II metabotropic glutamate (mGlu) receptor agonists, including (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), have demonstrated efficacy in animal models of anxiety and schizophrenia, and LY354740 decreased anxiety in human...
8.
Weiss B, Alt A, Ogden A, Gates M, Dieckman D, Clemens-Smith A, et al.
J Pharmacol Exp Ther
. 2006 May;
318(2):772-81.
PMID: 16690725
The excitatory neurotransmitter glutamate has been implicated in both migraine and persistent pain. The identification of the kainate receptor GLU(K5) in dorsal root ganglia, the dorsal horn, and trigeminal ganglia...
9.
Alt A, Weiss B, Ogden A, Li X, Gleason S, Calligaro D, et al.
Psychopharmacology (Berl)
. 2006 Feb;
185(2):240-7.
PMID: 16470401
Rationale: Although convergent evidence exists for a role of glutamate in the regulation of anxiety, the involvement of specific glutamate receptor subtypes has yet to be defined. Objective: To evaluate...
10.
Rasmussen K, Benvenga M, Bymaster F, Calligaro D, Cohen I, Falcone J, et al.
J Pharmacol Exp Ther
. 2005 Sep;
315(3):1265-77.
PMID: 16141369
FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene] is a potential novel antipsychotic with high affinity for dopamine D2 (Ki= 6.3 nM), 5-HT(2A) (Ki= 7.3 nM), and 5-HT6 (Ki= 8.0 nM) human recombinant receptors and lower...